EQT Life Sciences

Life sciences investor active in later-stage biotech rounds.

Profile being verified

Stage
Series A to Series C across recorded rounds
Ticket
Ticket sizes not disclosed; recorded rounds of USD 50 M to USD 152 M
Location
Not specified
Tracked rounds
3

What they look for

Existing investor in FoRx Therapeutics and Nouscom; participating in the Series B of Vaderis Therapeutics.

Recent investments

Recorded Swiss rounds: FoRx Therapeutics (Series A, USD 50 M, December 2025), Vaderis Therapeutics (Series B, USD 152 M, August 2026), Nouscom (Series C, USD 135 M, October 2026).

Rounds tracked by FundSwiss